ABCB4 and Cholestatic liver disease: Using intestinally biased FXR agonists may be a way to dissect the role of intestinal FXR-related repression of BA synthesis from hepatic FXR-related anti-inflammatory effects in the development of cholestatic liver disease in the Mdr2-/- mouse.